Stock of the Day

AbbVie (ABBV)

$284.59

-$0.21 (-0.1%)

Market Cap: $503.18B

About AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Bull Case

Here are some ways that investors could benefit from investing in AbbVie:

• AbbVie's investigational dual-targeting therapy ABBV-466 demonstrated higher endoscopic remission rates in moderate-to-severe Crohn's disease than either monotherapy at Week 12, with the treatment advantage widening by Week 24. This positive Phase 2a data, presented in October 2026, suggests the drug could become a differentiated next-generation immunology product that extends the company's leadership in inflammatory diseases, potentially outperforming its established blockbuster Skyrizi in future comparisons.
• The stock is currently trading at $288.66, which is near its 52-week high of $291.40, reflecting strong recent momentum and a 24% increase in 2026. This price performance is supported by a low beta of 0.24, indicating that AbbVie shares are significantly less volatile than the broader market, which may appeal to investors seeking stability in their healthcare portfolio allocations.
• AbbVie is set to present data from seven oncology assets at the 2026 ESMO Congress, marking its largest-ever presence at the event. This includes updates on antibody-drug conjugates and precision medicines for lung, colorectal, ovarian, prostate, and gastric cancers, providing multiple potential pipeline catalysts that could drive further valuation growth as the company expands its solid tumor portfolio.
• Analysts anticipate roughly 16% third-quarter revenue growth driven by established therapies and newer Parkinson's treatments, with the company having previously reported Q2 2026 revenue of $15.00 billion, beating consensus estimates. This consistent revenue growth, combined with a net margin of 9.80% in the most recent reported quarter, demonstrates the company's ability to maintain profitability while scaling its neuroscience and immunology franchises.
• AbbVie offers a dividend yield of 2.42% with a quarterly payout of $1.73 per share, providing a steady income stream for investors. The company's strong free cash flow generation, highlighted in recent comparisons with peers like Vertex Pharmaceuticals, supports its ability to maintain this dividend while continuing to invest in high-growth areas such as gene editing and pain management.

AbbVie Bear Case

Investors should be bearish about investing in AbbVie for these reasons:

• AbbVie is currently trading at a P/E ratio of 81.54, which is significantly higher than the broader market average, suggesting the stock may be overvalued relative to its earnings. This high valuation leaves little room for error if future earnings growth slows or if the company fails to meet the high expectations set by its recent stock price appreciation.
• The company's dividend payout ratio is reported at 195.48%, which indicates that AbbVie is paying out more in dividends than it is generating in net income. While this may be supported by free cash flow, a payout ratio exceeding 100% can signal potential strain on the company's ability to sustain dividend growth or reinvest in R&D without external financing.
• Recent insider activity includes significant share sales, such as EVP Nicholas Donoghoe selling 32,710 shares in August 2026 and EVP Perry C. Siatis selling 22,381 shares in February 2026. While insider sales are common, a pattern of executives reducing their ownership stakes can be interpreted as a lack of confidence in the stock's near-term upside or a desire to diversify personal wealth.
• AbbVie is navigating the loss of exclusivity for its top-selling drug, Humira, which has historically been a major revenue driver. Although the company has successfully transitioned to newer products like Skyrizi and Rinvoq, the ongoing pressure from generic competition and the need to replace lost revenue from Humira remains a significant risk to long-term earnings stability.
• The stock's 52-week low of $190.75 indicates that the shares have experienced significant volatility and drawdowns over the past year. Investors who purchased near the high may face substantial unrealized losses if the stock reverts to its mean, and the high beta of 0.24, while low, does not eliminate the risk of sharp corrections in response to negative clinical trial data or macroeconomic headwinds.

Recent News

• 3 Stocks With Yields Big Enough to Make Election Volatility Easier to Stomach (ABBV) (marketbeat.com)
• What Higher Interest Rates Mean for Dividend Stocks Like AbbVie and Pfizer (fool.com)
• Great News for AbbVie Stock Investors (fool.com)
• Great News for AbbVie Stock Investors (fool.com)
• AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst (benzinga.com)
• AbbVie's Lutikizumab Meets Pre-specified Endpoints In Phase 3 Hidradenitis Suppurativa Trial (rttnews.com)
• AbbVie Says Phase 3 Trial of Lutikizumab in Hidradenitis Suppurativa Meets Endpoints (finance.yahoo.com)
• AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True? (finance.yahoo.com)
• AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa (finance.yahoo.com)
• Jim Cramer and Ken Fisher Like This Healthcare Stock (finance.yahoo.com)